The European Medicines Agency (EMA), Europe's drug regulator, has recommended the addition of a rare type of spinal inflammation as a side-effect of US pharmaceutical company Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine, Reuters news agency reported on Thursday.
The EMA said its was also assessing reports of capillary leak syndrome following inoculation with Moderna's (Nasdaq:MRNA) COVID-19 vaccine.
According to the EMA, there is currently not enough evidence of a possible link between rare cases of multisystem inflammatory syndrome with mRNA vaccines, including Moderna's shot.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007